Literature DB >> 16333960

[Relationship of serum prostate-specific antigen and alkaline phosphatase levels with bone metastases in patients with prostate cancer].

Zhen-Lin Wang1, Xiao-Fang Wang.   

Abstract

OBJECTIVE: To investigate the relation of serum prostate-specific antigen (PSA) and alkaline phosphatase (ALP) levels to bone metastases in patients with prostate cancer.
METHODS: We made a retrospective study of 96 cases of prostate cancer with (29 cases ) and without (67 cases ) bone metastases and evaluated their initial levels of serum PSA and ALP as well as the radionuclide bone scan findings.
RESULTS: The median concentrations of serum PSA and ALP were both in the bone scan-positive patients statistically higher than in those the negative ones (P < 0.01). The percentages of the bone scan-positive patients with PSA > 20 microg/L or ALP > 90 U/L were also higher than those with PSA < 20 microg/L or ALP < 90 U/L (P < 0.01).
CONCLUSION: Prostate cancer patients with bone metastases have higher levels of PSA and ALP than those without. Radionuclide bone scan is necessary when the serum PSA level is > 20 microg/L and/or ALP level > 90 U/L.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16333960

Source DB:  PubMed          Journal:  Zhonghua Nan Ke Xue        ISSN: 1009-3591


  2 in total

1.  The role of serum osteoprotegerine in metastatic prostate cancer - a case control study.

Authors:  M Siampanopoulou; Mantani El; G Moustakas; A Haritanti; A Gotzamani-Psarrakou
Journal:  Hippokratia       Date:  2016 Apr-Jun       Impact factor: 0.471

2.  Cancer of the prostate presenting with diffuse osteolytic metastatic bone lesions: a case report.

Authors:  Innocent Lule Segamwenge; Nuru Kaddu Mgori; Safia Abdallahyussuf; Celia Nantume Mukulu; Philip Nakangombe; Paul Kioko Ngalyuka; Fred Kidaaga
Journal:  J Med Case Rep       Date:  2012-12-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.